title: [Hyperkinetic disorders in childhood and adolescence- an analysis of KinderAGATE 2009-2012].
abstract: OBJECTIVE
  This contribution evaluates the prevalence, medication use as well as age and sex distribution in inpatients with hyperkinetic disorders at the KinderAGATE hospitals for 2009-2012.
  
  
  METHODS
  The age, sex, leading diagnosis, prescribed medication, and dosage of each patient were recorded anonymously twice a year. They provide an outstanding epidemiological basis for the observation of the actual situation in child and adolescent psychiatry.
  
  
  RESULTS
  Compared to our patient collective, patients diagnosed with hyperkinetic disorders (25.5% Pat) were on average 2 years younger and received psychopharmacological treatment more often (statistically significant). Although male patients are dominant here (84.3% HPat, mean age 9.9 years vs. 15.7% HPat, 10.1 years), the same proportion of female and male patients received psychostimulant treatment (48.0% vs. 52.2%). Besides methylphenidate, amphetamine, and atomoxetine, the antipsychotics risperidone, pipamperone, and quetiapine were noticeably often prescribed.
  
  
  CONCLUSIONS
  Methylphenidate remains the drug of first choice in the treatment of ADHD. There is an upward trend in the proportion of patients being treated with antipsychotics, though this is not statistically significant. Because of the discrepancy between the available evidence and prescription practice in child and adolescent psychiatry, there is still a great demand for studies regarding long-term efficacy and side effects.
authors.forename: Benedikt
authors.initials: B
authors.lastname: Stegmann
authors.forename: Christian A
authors.initials: CA
authors.lastname: Rexroth
authors.forename: Katharina
authors.initials: K
authors.lastname: Wenzel-Seifert
authors.forename: Ekkehard
authors.initials: E
authors.lastname: Haen
mesh_terms: D000293:Adolescent; D000367:Age Factors; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005858:Germany; D006760:Hospitalization; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use; D056687:Off-Label Use; D017891:Pharmacoepidemiology; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012737:Sex Factors
chemical_list: D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D011619:Psychotropic Drugs; D008774:Methylphenidate